Quebec City, Canada, September 30, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS) an innovator in low temperature sterile reprocessing solutions for medical devices in healthcare settings, today outlined commercial progress in cleared markets, as well as gave details on the program to upgrade customers of the first generation sterilizer (TSO3 125L Ozone Sterilizer) to that of the new generation sterilizer commercialized by 3M, under the brand 3M™ Optreoz™ 125-Z Sterilizer. The Company also acknowledged being actively engaged in the US regulatory process for clearance of the product in the United States.
Starting in June 2011, TSO3 has shipped products to multiple markets, consistent with the 3M launch plan previously disclosed, and additional markets are planned to open prior to year-end. At the request of initial TSO3 125L Ozone Sterilizer’s customers, wanting to benefit from features of the 3M™ Optreoz™ 125-Z, TSO3 has recently launched its upgrade program in Canada, where the Company will offer an upgrade to existing customers at a reduced price.
“We are pleased and excited with our progress on multiple fronts and are receiving positive feedback from 3M™ Optreoz™ 125-Z users, confirming our belief that we have developed the superior sterilization solution”, said R.M. (Ric) Rumble, CEO of TSO3.
Mr. Robin Bouchard, Manager of Sterile Reprocessing of the CHUQ – Hotel-Dieu de Québec, commented: “We recently upgraded from the TSO3 125L Ozone Sterilizer to the new 3M™ Optreoz 125-Z Sterilizer and are already experiencing improved throughput. In addition to obtaining significantly shorter cycle times, the 3M™ Optreoz™ Sterilizer is improving our standard of care by allowing terminal sterilization of devices previously processed using a liquid chemical sterilization method. In the past, we used this liquid process close to the Operating Room up to 40 times a week, to reprocess short flexible endoscopes one at a time. Shortly after commissioning the 3M™ Optreoz™ Sterilizer, we have virtually eliminated the use of the liquid process, as these scopes are now terminally sterilized, along with additional devices, in the 3M™ Optreoz™ Sterilizer. Even though the sterilizer was recently installed, we already run up to eight loads a day and are very happy with this acquisition that supports our reputation of excellence in sterile reprocessing practices”, concluded Mr. Bouchard.
The Company also took the opportunity to comment on the ongoing regulatory activities for US clearance: “Our submission of June 30 of this year has had its initial review”, said Mr. Rumble. “As is common in this regulatory process, we are having productive communication with the agency and remain confident that we will obtain regulatory clearance for the 3M™ Optreoz™ Sterilizer. However, as stated in the past, timing of such an event cannot be predicted”.
TSO3 enables better health care through the development of innovative, low-temperature medical device sterilization systems and offers these solutions through licensing agreements to reputable channel partners for global commercial reach.
The TSO3 sterile reprocessing solutions answer the global and growing need for economical and fast turnaround of a wide range of medical instruments. These solutions address cutting-edge, high-demand devices – such as flexible endoscopes – and support the development of increasingly sophisticated medical devices and techniques.
At TSO3 ‘s core, is its ability to conduct rapid research, development and prototyping as well as validating biocompatibility and functionality of innovative medical reprocessing systems. TSO3 maintains a rigorous quality system as well as in-house expertise for regulatory submissions.
For more information about TSO3, visit the Company’s Web site at www.tso3.com
The CHUQ (Centre hospitalier universitaire de Québec) is one of the most important healthcare establishments in the province of Québec. It offers general healthcare, but also offers highly specialized services to the population of eastern Québec, comprising some two million people. Closely tied to the Université Laval and facing the future, the CHUQ is also devoted to teaching and research in its numerous centers of excellence, as well as in the evaluation of technologies and health intervention modes. It is driven by a dedicated team of experts comprising over 1,000 doctors, dentists and pharmacists, as well 9,000 other employees. The CHUQ includes L’Hôtel-Dieu de Québec, l’Hôpital Saint-François d’Assise and the CHUL (Centre hospitalier université Laval) and its Mother and Child Center, as well as five other healthcare centers.
Details regarding the CHUQ can be found at www.chuq.qc.ca
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
-30-Back to Posts